Effects of Corrective Versus Plank Exercises on Diastasis Recti

June 8, 2026 updated by: Riphah International University

Effects of Corrective Versus Plank Exercises on Strength, Inter Recti Distance and Pain in Females With Diastasis Recti

This study will be randomized clinical trial and will be conducted in Services Hospital and poly clinics. The total duration of treatment will be 12 weeks. Non-probability convenience sampling technique will be used and 56 participants will be recruited in study after randomization. The participants are randomly assigned to one of two groups: Group A performs corrective exercises focused on deep core engagement, while Group B performs plank exercises aimed at overall abdominal activation. Each group follows their respective regimen three times per week for 12 weeks. Baseline EMS and pelvic floor exercises are conducted for all participants to ensure core stability before the interventions begin. Outcome measures, including manual muscle testing (MMT) for strength, and the Numerical Pain Rating Scale (NPRS) for pain, are recorded both before and after the 12-week intervention. After data collection data will be analyzed by using SPSS version 25.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
56

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 6400
        • Recruiting
        • Services Hospital
        • Contact:
          • adeela arif, t-DPT
        • Principal Investigator:
          • Fazeela Tahir, MSPT(WH)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • If IRD is greater than 4cm and above
  • Postpartum females
  • Three months to three years postpartum with presence of diastasis rectus abdominis
  • Vaginal delivery
  • Multiparous
  • Pain greater than 6 on NPRS

Exclusion Criteria:

  • Subjects with any heart condition, respiratory condition
  • Any pelvic or abdominal surgery
  • Any neurological disease eg preeclampsia, epilepsy
  • Trauma to bowel or bladder
  • Prior history of physical therapy treatment for pelvic floor issues
  • Postpartum depression

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: corrective exercises
During weeks 1-4, the program emphasized low-load activation, including transversus abdominis (TrA) drawing-in activation, posterior pelvic tilting, and modified heel slides performed with strict abdominal control. In weeks 5-8, progression was achieved through increased hold times, higher repetitions, slower tempo, and the gradual introduction of light resistance or functional integration cues where tolerated. In weeks 9-12, participants progressed toward functional core integration and advanced control exercises such as dead bug variations,
Other: corrective exercises
restoration of trunk stability, and reduction of IRD through improved tensioning of the linea alba. During weeks 1-4, the program emphasized low-load activation, including transversus abdominis (TrA) drawing-in activation, posterior pelvic tilting, and modified heel slides performed with strict abdominal control. In weeks 5-8, progression was achieved through increased hold times, higher repetitions, slower tempo, and the gradual introduction of light resistance or functional integration cues where tolerated. In weeks 9-12, participants progressed toward functional core integration and advanced control exercises such as dead bug variations,
Experimental: PLANK EXERCISES
In weeks 1-4, the program began with modified plank positions using knee-and-elbow support and modified side planks, with short hold durations and adequate rest intervals. During weeks 5-8, hold times were progressively increased, and participants were introduced to controlled plank variations such as weight-shifts or arm reach tasks depending on tolerance and maintenance of neutral spine control. In weeks 9-12, progression was aimed toward longer holds and more advanced stabilization tasks, including leg lifts in plank and progression toward full plank positions
Other: Plank Exercise
In weeks 1-4, the program began with modified plank positions using knee-and-elbow support and modified side planks, with short hold durations and adequate rest intervals. During weeks 5-8, hold times were progressively increased, and participants were introduced to controlled plank variations such as weight-shifts or arm reach tasks depending on tolerance and maintenance of neutral spine control. In weeks 9-12, progression was aimed toward longer holds and more advanced stabilization tasks, including leg lifts in plank and progression toward full plank positions

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
NPRS
Time Frame: 12th week
The Numerical Pain Rating Scale (NPRS) is a subjective measure in which individuals rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain. The NPRS is a widely used patient reported outcome scale.27-29 The ordinal 11-point NPRS (0-no pain, 10-most intense pain) is the most commonly used version which has good test-retest reliability (r=.79-.96) in individuals with chronic pain and musculoskeletal pathology.
12th week
• MMT
Time Frame: 12th week
MMT is the most commonly used method for documenting impairments in muscle strength. Manual muscle testing is used in rehabilitation and recovery to evaluate contractile units, including muscles and tendons, and their ability to generate forces. Reliability of strength MMT grade of lower extremity is 66-0.90. There are six grades of MMT i.e. Grade 5 (Normal), Grade 4 (Good), Grade 3+ (Fair), Grade 2+ (Poor), Grade 1 (Trace) and Grade 0 (Zero)
12th week
inter-recti distance
Time Frame: 12th week
The subjects were in supine resting position with the knees bent at 90° and feet resting on the plinth, arms alongside the body. After instruction in how to perform an abdominal crunch the subjects were asked to raise the head and shoulders upwards until the shoulder blades cleared the table. One physiotherapist placed the fingers vertically on the subject's Linea Alba in a way that fingers widths could fit the distance between the internal borders of the two rectus abdominis muscles. Using the center of the umbilicus as a reference, measurements were taken in two previously marked locations: one being 2 cm above the umbilicus and the other being 2 cm below the umbilicus.
12th week
Oswestry Disability Index
Time Frame: 12th week
The Oswestry Disability Index (ODI) is defined as a validated metric that assesses a patient's perceived level of disability through a 10-question assessment, yielding a numerical score from 0 to 100, where higher scores indicate greater disability
12th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: adeela arif, t-DPT, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 23, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 23, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 27, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/24/0536

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings